Barclays’s Alpha Tau Medical DRTS Stock Holding History

Barclays’s Portfolio DRTS Stock Details DRTS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-16,000	Closed	-$144K	–	4872
2022 Q2	$144K	Sell	16,000 -61,756	-79%	-$553K	﹤0.01%	3594
2022 Q1	$918K	Buy	+77,756	New	+$914K	﹤0.01%	2482

Other funds holding DRTS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

EMG

ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

WANY

Wealthspire Advisors (New York) New York $12.7B AUM 17.31% 1-Year Est. Return

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Barclays's DRTS Position: Q3 2022 in Review

Barclays sold out of Alpha Tau Medical (DRTS) in Q3 2022, closing a stake of 16,000 shares — an estimated $144K sold.

Barclays first reported a position in DRTS in Q1 2022 and held it in 2 quarters. The position peaked at $918K in Q1 2022. 18 funds tracked by Wall St. Rank hold DRTS as of Q3 2022.

Barclays reported no remaining Alpha Tau Medical position as of Q3 2022 after selling out during the quarter.
Barclays sold 16,000 Alpha Tau Medical shares in Q3 2022, an estimated $144K.
Barclays first reported a position in Alpha Tau Medical in Q1 2022 and held it in 2 quarters.
Barclays's Alpha Tau Medical position peaked at $918K in Q1 2022.
18 funds tracked by Wall St. Rank held Alpha Tau Medical as of Q3 2022.

Based on Barclays's 13F filing for Q3 2022, filed 3 Nov 2022.